Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
Dow
Fuji
Cipla
Queensland Health
Cerilliant
Merck
Mallinckrodt

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,155,718

« Back to Dashboard

Which drugs does patent 9,155,718 protect, and when does it expire?

Patent 9,155,718 protects ADVIL PM and is included in one NDA.

This patent has eleven patent family members in ten countries.
Summary for Patent: 9,155,718
Title:Treatment of sleep disturbances
Abstract: The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.
Inventor(s): Cook; Graham D. (Midlothian, VA), Koch; Todd S. (Powhatan, VA), Giamalva; David H. (Glen Allen, VA), Bianco; Justin (Vineland, NJ), Fort; James J. (Midlothian, VA), Doyle; Geraldine (Chatham, NJ), Cooper; Steven (Denville, NJ)
Assignee: Wyeth LLC (New York, NY)
Application Number:14/504,159
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Drugs Protected by US Patent 9,155,718

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer ADVIL PM diphenhydramine hydrochloride; ibuprofen CAPSULE;ORAL 021393-001 Dec 21, 2005 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,155,718

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,263,647 Treatment of sleep disturbances ➤ Try a Free Trial
8,883,849 Treatment of sleep disturbances ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,155,718

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1363608 ➤ Try a Free Trial
Spain 2251584 ➤ Try a Free Trial
Japan 2004521104 ➤ Try a Free Trial
Hong Kong 1060045 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fish and Richardson
Harvard Business School
Boehringer Ingelheim
Express Scripts
Healthtrust
Medtronic
Accenture
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.